Tag Archives: BioGen Spinoff

Gabelli & Co Call Bioverativ(BIVV) Stock A Buy With A Value Of $58, Morgan Stanley Disagrees

By |
3 Comments

Bioverativ(BIVV), a drug company focused on hemophilia and other blood disorders, was spun off by Biogen(BIIB) last week. Gabelli & Co initiated Bivoerativ stock as a buy with a value of $58, citing the company’s strong balance sheet(no debt, $325 million in cash), its limited exposure to Medicare, its potential to benefit from corporate tax reform, and its… Read More »

BioGen Updates Its Spinoff Plans

By |
3 Comments

BioGen (BIIB) has finally chosen a name for its upcoming hemophilia drug focused spinoff. The new company will be called Bioverativ and it will eventually trade on the Nasdaq under the ticker ‘BIVV’. Bioverativ will be a global biotech company ‘focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.’ It’s growing… Read More »